# A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings

> **NCT04940039** · PHASE4 · COMPLETED · sponsor: **Janssen-Cilag International NV** · enrollment: 93 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Risperidone 3 mg
- **DRUG:** Paliperidone Palmitate 50 mg eq.
- **DRUG:** Paliperidone Palmitate 75 mg eq.
- **DRUG:** Paliperidone Palmitate 100 mg eq.
- **DRUG:** Paliperidone Palmitate 150 mg eq.
- **DRUG:** Paliperidone Palmitate 175 mg eq.
- **DRUG:** Paliperidone Palmitate 263 mg eq.
- **DRUG:** Paliperidone Palmitate 350 mg eq.
- **DRUG:** Paliperidone Palmitate 525 mg eq.

## Key facts

- **NCT ID:** NCT04940039
- **Lead sponsor:** Janssen-Cilag International NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-07-22
- **Primary completion:** 2024-04-16
- **Final completion:** 2024-04-16
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2025-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04940039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04940039, "A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings". Retrieved via AI Analytics 2026-09-28 from https://api.ai-analytics.org/clinical/NCT04940039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*